Hypothesis

Chronic pain triggers microglial NLRP3 inflammasome activation, which consumes NAD+ through PARP1 and CD38 activity, lowering SIRT1-mediated deacetylation of histone and metabolic regulators. This NAD+ decline drives DNA methylation shifts captured by epigenetic clocks (especially DNAmGrimAge) and produces a feed‑forward loop that heightens pain sensitivity. Restoring NAD+ should break the loop, reducing both pain hypersensitivity and epigenetic age acceleration.

Mechanistic Reasoning

• Microglial priming: Persistent nociceptive signaling activates microglia via TLR4 and P2X7 receptors, leading to NLRP3 inflammasome assembly (6).
• NAD+ consumption: Activated NLRP3 stimulates PARP1 (DNA damage response) and upregulates CD38, both major NAD+ hydrolyzing enzymes (1).
• SIRT1 suppression: Lower NAD+ reduces SIRT1 deacetylase activity, increasing acetylation of NF‑κB and histones, promoting a pro‑inflammatory transcriptome and altering DNA methyltransferase recruitment (3).
• Epigenetic outcome: SIRT1 loss correlates with GrimAge acceleration; NAD+ repletion rescues SIRT1 function and normalizes methylation patterns in aging models (4).
• Pain phenotype: Heightened microglial IL‑1β release sensitizes peripheral nociceptors, lowering heat and pressure thresholds; NAD+ boost attenuates cytokine release and restores nociceptive balance (2, 5).

Testable Predictions

1. Animals with induced chronic pain (CFA or SNI) will show increased microglial NLRP3 protein, elevated PARP1/CD38 activity, and reduced hippocampal NAD+ levels compared to controls.
2. NAD+ depletion will correlate positively with DNAmGrimAge acceleration in the same tissues.
3. Pharmacological NAD+ supplementation (e.g., nicotinamide riboside) or genetic SIRT1 overexpression will normalize NAD+, reduce inflammasome markers, lower DNAmGrimAge, and raise pain thresholds.
4. Conversely, NAD+ depletion (via FK866) in pain‑free animals will reproduce pain hypersensitivity and epigenetic age acceleration.

Experimental Design

• Subjects: Male and female C57BL/6 mice, 3‑month‑old, n=10 per group.
• Groups: (1) Sham, (2) Chronic pain (CFA hind‑paw), (3) Pain + NAD+ booster (NR 400 mg/kg/day), (4) Pain + SIRT1 inhibitor (EX‑527), (5) NAD+ depleted (FK866) alone.
• Timeline: Pain induction day 0, treatments start day 3, assessments on days 7, 14, 28.
• Readouts:
  • Mechanical (von Frey) and thermal (Hargreaves) pain thresholds.
  • Microglial Iba1 and NLRP3 immunoblotting/histochemistry.
  • NAD+ quantification via LC‑MS/MS.
  • PARP1 activity, CD38 expression.
  • SIRT1 activity (deacetylation assay).
  • Epigenetic age: mouse blood/tissue DNAmGrimAge surrogate (using published CpG set).
  • Serum IL‑1β, TNF‑α.
• Statistics: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

Potential Outcomes & Falsifiability

• Support: NAD+ booster reverses pain hypersensitivity and GrimAge acceleration; NAD+ depletion induces both phenotypes in naïve mice.
• Refute: No change in NAD+ levels or inflammasome markers despite pain manipulation; NAD+ modulation fails to affect thresholds or epigenetic age; or epigenetic age shifts occur independently of NAD+ flux.

This framework converts a correlational observation into a causal, metabolite‑centric mechanism that can be directly challenged by pharmacological or genetic interventions, advancing pain sensitivity as a functional biomarker of biological aging.